Full-Time
Account Partner
Development Cloud, Medical Device & Diagnostics
Veeva Systems
10,001+ employees
Cloud-based quality, regulatory, and claims management
Compensation Overview
€110k - €220k/yr
Paris, France
Remote
Must reside in France; remote from home.
Bachelor's
 Biology & Biotech (1) |
|---|
 Growth & Marketing (1) |
|---|
Get referred to Veeva Systems
See people who can refer or advise you
- 7+ years of work experience, 5+ years of sales or business development experience (preferably software sales, SaaS, professional services selling to Medtech & Diagnostics customers)
- Experience managing & growing a territory with 5-7 enterprise customers & strategic prospects (prospecting & expansion, identification & qualification skills, managing various transactions, e.g. new business, expansion, renewal)
- Self-starter with organizational skills & team player attitude
- Good communication skills to quickly connect with new customers & prospects (maneuver easily between different hierarchical levels e.g. VP, Director, Manager Level)
- Bachelor’s degree or above
- Language – English & French (fluent, native)
- Located in France
- Develop and execute territory sales strategy for Veeva DevCloud offerings
- Contribute to Team Quarterly and Annual Sales Goals
- Meet and exceed your assigned revenue quota
- Analyze & understand customers’ vision & business objectives and relate them to Veeva’s solutions
- Focus on lead & pipeline generation, manage sales process through contract negotiation/execution to delivery handoff
- Work both independently and cohesively in a team environment
- Report and maintain territory & account strategy incl. respective opportunity management
- Detailed process knowledge within e.g. Clinical Operations, Clinical Data or Regulatory domain within the Medical Device & Diagnostics Industry
Veeva Systems provides cloud-based software that helps consumer goods and chemical companies manage quality, regulatory compliance, and advertising claims. The platform works by connecting different departments—from the supply chain to marketing—to provide a single source of data that tracks a product's journey and ensures it meets safety standards. Unlike competitors that offer general business tools, Veeva specializes in navigating the highly complex regulations originally found in the life sciences sector and applies that specific expertise to other regulated industries. The company's goal is to help businesses bring safe, sustainable, and compliant products to market faster by providing end-to-end visibility and traceability.
Company Size
10,001+
Company Stage
IPO
Headquarters
Pleasanton, California
Founded
2007
Get referred to Veeva Systems
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q1 fiscal 2027 revenue reached $882.9 million on June 3, 2026.
- Veeva acquired Copli on June 23, 2026, targeting 70% manual MLR labor elimination.
- Veeva EHS entered early adopter availability in August 2026, widening Quality Cloud adoption.
What critics are saying
- Lilly concentration rises as Veeva leans harder on top-pharma CRM commitments in 2026.
- Thomas Schwenger exits October 2026, risking sales execution during the Vault CRM expansion.
- Salesforce and AI-native workflow vendors can compress CRM switching costs and margins by 2027.
What makes Veeva Systems unique
- Veeva owns life-sciences workflows from clinical through commercial, not generic horizontal SaaS.
- Vault CRM underpins Lilly’s global rollout and Veeva’s agentic commercial strategy, announced August 11, 2026.
- Falcon MLR and Veeva EHS extend one platform across regulatory, quality, and safety.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Parental leave
PTO
Free food
Health, dental, & vision insurance
Gym membership reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Veeva Systems has secured a global deployment commitment for Vault CRM from Eli Lilly. The company also announced that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, with Dan Rizzo succeeding him as EVP of Sales, Consulting, and Services. Wall Street analysts expect higher quarterly earnings and revenue for Veeva. The Eli Lilly deployment reinforces the trend of top pharmaceutical companies consolidating commercial workflows on Veeva's platform. Analysts project Veeva will reach $4.5 billion in revenue and $1.3 billion in earnings by 2029, requiring 12.7% annual revenue growth. However, investors should note the company's concentrated exposure to major CRM customers. AI agents in safety and clinical workflows remain a potential factor that could affect both forecasts and investor confidence.
Veeva Vault CRM selected by Eli Lilly and Company. Aug 11, 2026, 07:03 ET PLEASANTON, Calif., Aug. 11, 2026 /PRNewswire/ - Veeva Systems (NYSE: VEEV) today announced that Eli Lilly and Company (Lilly) has selected Veeva Vault CRM globally. Vault CRM is part of the Vault CRM application suite, which forms the technological foundation for "Agentic Commercial" - the new sales model that uses AI to help more patients get the right medications. "We are very excited to expand our strategic collaboration with Veeva by transitioning to Vault CRM," said Giuseppe Firenze, Senior Vice President of U.S. HCP and Field Engagement Hub at Lilly. "Vault CRM will help Lilly make our breakthrough medications accessible to more patients." "Lilly develops medicines that improve the lives of people around the world," said Peter Gassner, CEO of Veeva. "We are proud to expand our strategic collaboration with Lilly as part of the global rollout of Vault CRM." Learn more about the Veeva Vault CRM suite, including the Agentic Call Report for generating commercial evidence, at veeva.com/crm. About Veeva Systems Veeva provides the industry cloud for life sciences with applications, agents, data, and consulting. Veeva is committed to innovation, product quality, and customer success, serving more than 1,500 customers, from the world's largest pharmaceutical companies to emerging biotech companies. As a Public Benefit Corporation, Veeva is dedicated to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com. Forward-looking statements of Veeva This press release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from the use of our products and services. These statements are based on our current expectations. Actual results may differ materially from those described in this press release, and we undertake no obligation to update such statements. There are numerous risks that could potentially negatively affect our results, including the risks and uncertainties disclosed in our Form 10-Q for the fiscal quarter ended April 30, 2026 - available here (see pages 33 and 34 for a summary of risks that could affect our business) - as well as in our subsequent SEC filings, which you can access at sec.gov. Contact: Maria Scurry Veeva Systems [email protected] Meera Lakhani-Patel Veeva Systems, Europe [email protected]
Vulcan Value Partners added Veeva Systems to its All-Cap strategy in Q2 2026, describing the company as the dominant vertical market software system of record for the life sciences industry. The investment firm noted that Veeva's customers rely on its platform to run their entire business, from drug development and regulatory approval to manufacturing, selling, and marketing. Veeva grew revenue and EBIT by 16% and 24% respectively in 2025 and maintained strong momentum into 2026. Despite these results, the stock fell nearly 20% year-to-date through end-June, moving in sympathy with the broader application software sector. On 29 July 2026, Veeva shares closed at $207.91, giving it a market capitalisation of $33.77 billion. According to data, 62 hedge funds held Veeva at the end of Q1, down from 75 in the previous quarter.
IDDI joins Veeva CRO Partner Program to expand eClinical technology offerings for clinical trials. July 17, 2026. BRUSSELS; RALEIGH, N.C.; July. 16, 2026 - IDDI today announced it has joined the Veeva CRO Partner Program, further expanding its eClinical technology ecosystem to support sponsors running clinical trials of all sizes and complexities. As a leading provider of biometrics services, including biostatistics, data management, RTSM, and strategic consulting, IDDI is committed to helping sponsors select the technologies that best fit their protocol requirements and operational needs. Through this partnership, IDDI will expand the range of eClinical solutions available to its customers by adding Veeva Clinical Data applications, including Veeva EDC, Veeva DQS, Veeva eCOA, and Veeva RTSM. By combining scientific expertise with advanced technology solutions, IDDI helps sponsors build efficient, scalable clinical trial strategies that support high-quality data collection, streamlined study execution, and successful clinical outcomes. "Sponsors need the flexibility to build clinical technology ecosystems that support their unique study requirements," said Tara Kervin, Chief Operating Officer at IDDI. "By joining the Veeva CRO Partner Program, we are expanding our eClinical technology portfolio with Veeva's EDC, DQS, eCOA, and RTSM solutions. Together, we can better align technology with protocol design, giving sponsors greater choice while helping them execute studies more efficiently and confidently." The partnership reflects a shared commitment to providing life sciences organizations with modern, connected solutions that support efficient trial execution and enable teams to manage increasingly complex studies with confidence. About IDDI IDDI is a trusted clinical data science partner. With 35+ years of research-driven experience, IDDI Inc. combine therapeutic expertise, biostatistical leadership, and regulatory insight to mitigate risk from design to registration and beyond. IDDI Inc. deliver uncompromising excellence in biostatistics, strategic consulting, clinical data management, IDMCs, and supporting eClinical technologies, because when every data point represents a patient, perfection is the only option.
Stifel has reiterated its Buy rating and $230 price target on Veeva Systems following the company's acquisition of Copli, an agentic medical, legal and regulatory solutions firm. Veeva rebranded the acquisition as Veeva Falcon MLR, claiming the solution can eliminate 70% or more of manual MLR labour within five years. The system conducts compliance checks on promotional and medical materials against approved labels and local regulations. Separately, Veeva launched Veeva EHS on 25 June, a new environmental, health and safety application within its Veeva Quality Cloud. Veeva Systems delivers industry cloud solutions for life sciences, offering software, AI, data and consulting services.